**Pivot Pharmaceuticals to Launch Pivot Naturals 1% Oral CBD Solution in European Market**

***Initial Order of 15,000 Bottles to Be Sold Via Distribution Partner S.T.U. GmbH***

VANCOUVER, BC - (November 14, 2018) – [Pivot Pharmaceuticals Inc](http://www.pivotpharma.com/). (CSE: [PVOT](http://thecse.com/en/listings/life-sciences/pivot-pharmaceuticals-inc) / OTCQB: [PVOTF](https://www.otcmarkets.com/stock/PVOTF/quote) / FRA: [NPAT](https://markets.ft.com/data/equities/tearsheet/summary?s=NPAT:FRA)) (“Pivot” or the “Company”) is pleased to announce that it has placed a Purchase Order with its German manufacturing partner, Solmic GmbH, for 15,000 bottles of Pivot Naturals Oral 1% CBD Solution. The product will be distributed in the European Union to over 1,800 retail and online clients by Pivot’s distribution partner, S.T.U. GmbH. The 30 ml bottle will retail for CHF 90.00 and be available for purchase in December 2018. The product is registered in Germany and has the required Pharmazentralnummer (PZN) code. Once a product is introduced in the IFA database, a Pharmazentralnummer (PZN) is assigned. It is the national standard identification code for products in the pharmacy market in Germany and makes the products eligible for sale in other EU countries.

**Highlights:**

* **Pivot places Purchase Order for 15,000 bottles of ‘Pivot Naturals 1% Oral CBD Solution’;**
* **Patented solubilisation technology renders the CBD water-soluble, ensures stability and increases bioavailability;**
* **‘Pivot Naturals 1%’ available in 30 ml dropper bottle format and will retail for CHF 90.00;**
* **S.T.U. GmbH to distribute Pivot Naturals 1% Oral CBD Solution in Austria, Germany, Italy, Switzerland and the U.K. through 1,800 retail points of sale and e-commerce platforms.**

Pivot Naturals 1% Oral CBD Solution is formulated using a patented solubilisation technology that renders the CBD water soluble, ensures stability, and offers high bioavailability. The natural extract contains CBD in its highest purity (>99.6%) and is devoid of THC and other cannabinoids. Health conscious consumers are quickly becoming educated with respect to the different attributes of product offerings currently in the marketplace. Patented drug delivery platforms that create quality products and fulfill the health and wellness needs of consumers will ultimately validate Pivot’s sustainable and profitable business model.

Dr. Patrick Frankham, Pivot’s CEO, stated, “With this initial Purchase Order from Europe, Pivot has completed another important milestone. In one year, the Company has successfully transitioned from acquiring patented formulation and delivery technologies to commercializing our catalogue of differentiated bio-cannabis products and initiating sales. Cannabis is an entirely new market and we are paving the way for premium science-based products consumers will demand. With recently announced sales channels and joint venture partners in Latin America, Europe and Canada, across pharmaceutical and beverage markets, Pivot is well positioned to rapidly capture global market share in the emerging industry.”

**About Pivot Pharmaceuticals Inc.**

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired “RTIC” Ready-To-Infuse Cannabis oil-to-powder technology and Thrudermic Transdermal Nanotechnology (transdermal); acquired worldwide rights to BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral), and Solumer™ Oral Drug Delivery technology; and an option to acquire worldwide rights to TriVair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. For more information please visit [www.PivotPharma.com](http://www.PivotPharma.com)

**Cautionary Note Regarding Forward-Looking Statements**

*Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot's products, statements with respect to internal expectations, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.*

**Contact Information:**

Pivot Pharmaceuticals Inc.

Patrick Frankham, PhD, MBA

Chief Executive Officer

Email: [info@pivotpharma.com](mailto:info@pivotpharma.com)

Virtus Advisory Group

Shareholder Inquiries

Email: [pivot@virtusadvisory.com](mailto:pivot@virtusadvisory.com?subject=Pivot%20Pharma)

Phone: 416-644-5081